Rare Disease Economics and Orphan Drug Commercialization
With your login credentials (included on your program guide), attendees of the 2014 conference
can access the 2014 presentations here.
Purchase access to the latest World Congress Summit on Rare Disease Economics and Orphan Drug Commercialization through our Compendium Website and gain access to all speaker-provided content for ONLY $198!
Rare Disease Economics and Orphan Drug Commercialization
Rare disease has long been an important field for biotech and pharmaceutical manufacturers. With few competitors in the space for specific molecules and indications, brands have historically maintained significant influence on market and pricing indicators. Recent increases in regulatory approvals, reduced development timelines, and an array of commercial incentives have enhanced the value of orphan drugs and created an explosion in the space. As more and more orphan drugs are being added and removed from formularies, market access dynamics are shifting into a greater unknown.
These forces have created the need for a renewed understanding of the commercial economics of rare disease and orphan drugs so that manufacturers can forecast and commercialize products successfully. This Summit evaluates these forces, their economic impact, and the implications for orphan drug development, patient access, market access, pricing, and reimbursement.
In the past five years, 39 orphan drugs were launched in the US across numerous therapeutic categories, including multiple myeloma, chronic myelogenous leukemia, metastatic non-small cell lung cancer, hemophilia, tuberculosis, homozygous familial hypercholesterolemia, and cystic fibrosis. In 2013 alone, nine orphan drugs were approved, the most in a single year. The growing number of commercially available orphan drugs and the high cost of various orphan treatments have led to reconsideration of payer reimbursement policies.
Top Reasons to Attend:
- Assess methods to increase orphan drug speed to market at a lower price to the patient
- Discuss the impending economic evolution in the rare disease landscape with senior executives
- Understand factors affecting reimbursement and formulary decisions
- Benchmark strategies for pricing and cost saving valuation of orphan drugs
- Discover recent findings on global orphan drug patient access issues
See the Attendee List of the 2014 Summit
Testimonials from attendees of the 2014 Summit:
“Well worth my time – I learned a great deal – unique and innovative forum.” – Gil Litalien, PhD, Executive Director
“The World Congress on Economics and Orphan Drug Commercialization was a wonderful opportunity to interact with senior level industry and government executives to concentrate on solutions to common problems in commercial development.” – Anne Marie Finley, MS, President, Biotech Policy Group, LLC
“This was the most content-consistent meeting with excellent information exchange, consistent in quality delivery. The speakers and presentations were clear and valuable.” – Haya Taitel, Vice President, New Product Commercialization, Kadmon
“It is imperative that our industry stakeholders come together in forums like this conference and address the issues we face. Together we can make a difference.” – Dave Reynolds, Vice President, Praxis Rx Health Services
“The two day summit was very informative about the specifics of commercialization. The speakers were knowledgeable and offered future focuses required in the rare disease specialties.” – Cherylann Gregory, CEO and President, Specialty Pharmacy Nursing Network
“Great discussion addressing the challenges in the orphan drug market.” – Marcel van Kuijck, PhD, Senior Director and Global Head, Rare Disease Registries, Genzyme, a Sanofi Company
“Super!” - Charles Shasky, President, Biotechnomics; Head, Pharmacoeconomic Comparative Effectiveness Research, Aetna
Call for Papers: Submit Abstracts for Presentations
Rare Disease Economics and Orphan Drug Commercialization is now accepting abstract submissions for 2015! Deadline is May 29th, 2015. Click here for details.
To Inquire about Sponsorship and Executive Networking Opportunities, contact:
Suzanne Carroll
Business Development Manager
781-939-2648
[email protected]
